NasdaqGS - Nasdaq Real Time Price ? USD iRhythm Technologies, Inc. (IRTC) Follow Compare 76.50 +4.06 (+5.60%) As of 3:27 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Here’s Why iRhythm Technologies (IRTC) Slid in Q3 Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund appreciated 5.81%% (Institutional Shares) in the quarter compared to a 6.74% gain for the Russell 3000 Health Care Index (benchmark) and a 6.23% gain for the Russell […] Insider Monkey ? 6 hours ago IRTC +5.60% iRhythm Technologies, Inc. (NASDAQ:IRTC) Just Reported, And Analysts Assigned A US$101 Price Target Last week, you might have seen that iRhythm Technologies, Inc. ( NASDAQ:IRTC ) released its quarterly result to the... Simply Wall St. ? 6 hours ago IRTC +5.60% FDA clears iRhythm’s second 510(k) in response to warning letter However, the company said it will delay a submission for its next-generation Zio cardiac monitoring system until remediation efforts are further along. MedTech Dive ? 7 hours ago IRTC +5.60% iRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... iRhythm Technologies Inc (IRTC) reports robust revenue growth and international expansion, while navigating regulatory hurdles and strategic delays. GuruFocus.com ? yesterday IRTC +5.60% IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -129.09% and 0.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? yesterday IRTC +5.60% iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio? AT Device Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510(k)-cleared enhancements will be available in 2025 SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and GlobeNewswire ? yesterday IRTC +5.60% iRhythm Technologies Announces Third Quarter 2024 Financial Results SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $147.5 million, an 18% increase compared to third quarter 2023Gross margin of 68.8%, a 260-basis point increase compared to third quarter 2023Unrestricted cas GlobeNewswire ? yesterday IRTC +5.60% Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting about 1 in 500 people and is one of the leading causes of sudden cardiac death (SCD) in people under 35, including among athletes.1NSVT (nonsustained ventricular tachycardia), a known marker for increased risk of SCD in HCM, was detected in nearly 50% of HCM patients in the study undergoing long-term continuous ambulatory ECG monitoring of up to 14 days with a Zio? XT LTCM ECG patch device; 63% of NSVT episodes detected onl GlobeNewswire ? 4 days ago IRTC +5.60% iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock? iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 9 days ago IRTC +5.60% SDGR iRhythm’s Zio AT design changes win FDA clearance The agency cleared one of two 510(k) submissions iRhythm filed for the heart monitor after receiving a warning letter from the agency last year. MedTech Dive ? 9 days ago IRTC +5.60% With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says On Monday, the FDA approved iRhythm Technologies, Inc.’s (NASDAQ:IRTC) 510(k) submission related to prior design changes to the Zio AT device via letter to file. Zio AT remains commercially available to ship to customers in the United States. “We are pleased to have received this first 510(k) clearance in line with the sequence of how we submitted the first of two 510(k)s at the beginning of this year, and we look forward to hearing about our second 510(k) in the near future,” said Quentin Black Benzinga ? 10 days ago IRTC +5.60% iRhythm's Stock Skyrockets 17% After Game-Changing FDA Approval -- Is This Just the Beginning? iRhythm secures crucial FDA clearance for its Zio AT device, setting the stage for growth and fueling investor excitement over the future of cardiac monitoring technology GuruFocus.com ? 10 days ago IRTC +5.60% iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance. Zacks ? 10 days ago IRTC +5.60% ADUS DGX iRhythm shares soar after FDA clears Zio AT device updates Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) surged 10.6% in pre-market trading on Tuesday after the company said that it had secured U.S. Food and Drug Administration clearance for updates made to its Zio AT device. The clearance follows a 510(k) submission related to design modifications that had previously been filed under a "letter to file," ensuring the cardiac telemetry device remains available for use in the United States. Truist had recently lowered their valuation due to uncertainties related to the FDA and regulatory overhangs, including potential delays with the two Zio AT 510(k) submissions. Investing.com ? 10 days ago IRTC +5.60% iRhythm secures 510(k) clearance for Zio device updates after FDA warning iRhythm received a warning letter from the FDA in May 2024, citing violations of the United States Federal Food, Drug, and Cosmetic Act. Medical Device Network ? 10 days ago IRTC +5.60% iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio? AT Device Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patientsSAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its 51 GlobeNewswire ? 10 days ago IRTC +5.60% iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024 SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a liv GlobeNewswire ? 15 days ago IRTC +5.60% iRhythm Technologies (IRTC) Slipped on Regulatory Issues Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return of 2.38%, and Institutional Class fund APHMX returned 2.40%, compared […] Insider Monkey ? 16 days ago IRTC +5.60% Irhythm Technologies Outlines Growth and Market Leadership Strategy Irhythm Technologies ( (IRTC) ) has issued an announcement. iRhythm Technologies, Inc. has actively engaged its shareholders with an investor presentation outlining its achievements and strategic focus areas, including market expansion opportunities, innovation, and operational efficiency to enhance long-term shareholder value. The company emphasizes its strong market position, with a 70% share in long-term continuous monitoring and significant expansion both domestically and internationally. Ad TipRanks ? 21 days ago IRTC +5.60% iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology. Zacks ? last month IRTC +5.60% UHS DGX Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IRTC S&P 500 YTD -28.53% +20.31% 1-Year -2.57% +36.83% 3-Year +9.07% +24.60%
